Clinical Trials Browser

Phase 3 × INDUSTRY × orelabrutinib × Clear all

NCT06082102 2025-09-15

Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma

Phase 3 Recruiting

Lymphoma, B-Cell, Marginal Zone

NCT06363994 2024-12-27

A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL

Phase 3 Recruiting

Lymphoma, Mantle-Cell

NCT05234684 2024-02-07

BELIEVE-01

Phase 3 Unknown

Lymphoma, Large B-Cell, Diffuse